INTRODUCTION
Peripheral nerve sheath tumors (PNSTs) around the pelvis are relatively uncommon (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Benign peripheral nerve sheath tumors (BPNSTs) in this region may develop large tumoral mass and may display marked nuclear atypia on a degenerative basis; as a result, differential diagnosis between benign and malignant peripheral nerve sheath tumors (MPNSTs) remains a challenge. Preoperative pathological diagnosis based on limited samples is particularly difficult when evaluating the degenerative features of tumors (1, 2, 6) . Although a few series of studies exist on clinical features of pelvic benign schwannomas (1, 5) , details of clinical, imaging and histological features of MPNSTs around the pelvis have been scarcely reported. The purpose of this study was to determine the value of clinical signs, imaging features, biopsy and immunohistochemical evaluation in terms of differentiation of BPNST from MPNST around the pelvis.
SUBJECTS AND METHODS

CLINICAL DATA
All patients at our institution diagnosed with and treated for BPNST or MPNST around the pelvis between 1980 and 2002 were reviewed. The tumors arose from the retroperitoneal, sacral, presacral, buttock and inguinal regions. Thirty patients presented with PNSTs, including 16 benign schwannomas, three neurofibromas and 11 MPNSTs. Clinical charts, preoperative images and histologic slides of all the 30 cases were reviewed. Strict criteria were used for the diagnosis of MPNST. The malignant neoplasms appeared to arise in a nerve or in patients displaying typical neurofibromatosis.
Muscle strength was graded from 0 (no activity) to 5 (normal) on manual muscle testing (MMT) (12) . The worst grade of the affected muscle was recorded.
Preoperative computed tomography (CT) scans were available for review in all but one patient (15 schwannomas, 3 neurofibromas and 11 MPNSTs). Axial sections (5 or 10 mm in thickness) were obtained from all patients. Magnetic resonance imaging (MRI) of 24 patients (13 schwannomas, 2 neurofibromas and 9 MPNSTs) was performed by employing a variable system with varying field strength (0.5 to 1.5 T). Conventional scanning sequences included T1-weighted (400-700/15-32) and T2-weighted (1700-3300/80-110) spin echo sequences.
HISTOLOGIC DATA
Fine needle aspiration was performed with an 18-gauge needle with or without image guidance. Core biopsy was conducted with an 18-gauge needle (ASAP Detachable, Boston Scientific Corporation, Watertown, MA, USA) with or without image guidance. Each specimen (resected specimens and biopsy materials) was stained with routine hematoxylin and eosin. Immunoperoxidase methodology in terms of a Simple Stain MAX PRO system (Nichirei, Tokyo, Japan) was employed. Immunohistochemical reagents utilized in this study included primary monoclonal antibodies against Ki-67 (MIB-1) and a polyclonal antibody against S-100 protein (Dako, Tokyo, Japan). 
RESULTS
The results are summarized in Tables 1, 2 
ined in this series. The maximum dimension of individual tumors ranged from 4 to 20 cm; median size was 9 cm. Six, nine and four patients displayed sacral and presacral tumors, retroperitoneal tumors and buttock tumors, respectively. Six tumors arose from the sacral nerve root, five from the sciatic nerve, four from the femoral nerve, three from the lumbosacral plexus and a single tumor arose from the genitofemoral nerve. Direct connection with a major nerve was not identified in one patient with NF1. Fifteen patients complained of pain at rest. Ten patients demonstrated sensory disturbance and six patients exhibited faint to mild motor weakness (MMT 4, five patients; MMT 3, one patient). The duration of symptoms ranged from 2 to 120 months (median, 12 months).
MPNST
Of the 11 cases of MPNST, seven patients displayed NF1. The maximum tumor size ranged from 9 to 17 cm (median, 12 cm). Age at surgery ranged from 16 to 61 years (median, 34 years). Retroperitoneal tumors were present in seven patients; furthermore, sacral and presacral tumors were observed in a single patient, whereas three patients exhibited buttock tumors. Three tumors arose from the lumbo-sacral plexus, two from the sciatic nerve, two from the femoral nerve, and a single tumor arose from the S2 root. Direct connection with a major nerve was not identified in three patients diagnosed with NF1.
All patients complained of pain at rest; additionally, eight and seven patients displayed sensory disturbance and faint to severe motor weakness (MMT 4, one patient; MMT 3, two patients; MMT 2, two patients; and MMT 0, two patients), respectively. The median duration of symptoms was 12 months (range, 3 to 96 months).
IMAGING FINDINGS
BPNST
Eighteen patients underwent examination by CT. All tumors, which were slightly hypodense relative to muscle, possessed smooth margins. Six of these tumors arose from sacral nerve roots, or the eroded sacral foramen of the individual nerve root. The margins of the tumors in the sacrum were sharp and marginal sclerosis was observed in these six cases. Eight tumors were homogenous, whereas 10 tumors were heterogeneous. Six tumors exhibited small, mineralized areas. Contrastenhanced studies were available in all 18 cases; furthermore, nine cases displayed a round to irregular enhancement at the center of the tumoral mass or center of the nodules in the tumor (central enhancement) (Fig. 1A) . Five tumors showed peripheral enhancement (Fig. 1B) ; irregular and homogenous enhancement were evident in three and one tumor, respectively.
On T1-weighted MR images, 14 tumors were iso-to hypointense with muscle. On T2-weighted images, all tumors revealed inhomogeneous hyperintensity; moreover, peripheral hyperintense rim and central low intensity (target sign) (Figs 2A, C) were detected in four of the 14 tumors. Central enhancement was observed in six of the 14 cases involving Gd-DTPA administration (Figs 2B, D) . Massive cystic, hemorrhagic or necrotic degeneration (degenerative schwannoma) was apparent in five cases.
MPNST
CT features of 11 MPNSTs were reviewed. Eight tumors possessed smooth margins, and three were invasive. No MPNST showed central enhancement, whereas seven displayed irregular enhancement and peripheral enhancement was evident in four ( Figs 1C, D) .
MRI features of eight MPNSTs were reviewed. On T1-weighted images, all tumors were isointense with muscle; furthermore, all but one tumor possessed smooth margins. On 
PREOPERATIVE BIOPSY AND CYTOLOGY
A histological diagnosis was made prior to or during operation in all cases. Open biopsy was performed in 15 cases (10 BPNSTs, five MPNSTs). Six of these cases were diagnosed by intra-operative frozen section. All permanent sections of biopsy were accurately diagnosed; however, one MPNST was diagnosed as benign schwannoma by frozen section. Fine needle aspiration cytology (FNA) was performed in five BPNSTs and six MPNSTs. Of these 11 cases, CT guided procedure was conducted in four patients. Only four tumors were accurately diagnosed. Five samples did not yield adequate information, and additional open biopsy was performed. One schwannoma was diagnosed as spindle cell sarcoma; furthermore, one MPNST was diagnosed as neurofibroma by FNA. Four schwannomas and a single MPNST were accurately diagnosed by core needle biopsy. All needle biopsy procedures resulted in temporary radiating pain; however, neurological deficits were not observed.
PATHOLOGIC FINDINGS AND IMAGING CORRELATION
Of the 16 schwannomas, 14 tumors were classic schwannomas with Antoni A and B areas, and two neoplasms were cellular variants. Mitotic structures were scarcely observed in all schwannomas. The central enhancement in the BPNSTs, which was apparent in classic schwannoma or neurofibroma, corresponded to the central location of the hypercellular Antoni A area (Fig. 3A) or compact, packed tumor cells and collagen in neurofibroma. Peripheral enhancement in BPNSTs usually corresponded to cystic or hemorrhagic degeneration of the degenerative schwannomas. Peripheral enhancement in MPNSTs corresponded to peripheral location of vivid tumor tissues and central necrosis (Fig. 3B ). One MPNST with central enhancement displayed a relatively hypercellular area at the center of the tumor. One MPNST showed rhabdomyoblastic differentiation (Malignant Triton Tumor, Case M5).
IMMUNOHISTOCHEMICAL RESULTS
Immunohistochemical staining results for S-100 protein and Ki-67 are illustrated in Table 2 . All 19 BPNSTs displayed diffuse immonoreactivity for the S-100 protein.
No BPNST exhibited nuclear staining of Ki-67 exceeding 4% (median, 1.2%). In six of the 11 MPNSTs, S-100 protein was positive; however, the positive cells were focal in all six instances. 7-38% of the tumor cell nuclei revealed immonoreactivity for Ki-67 in MPNST (median, 23%) ( Figs 4A-G) . Age, association of NF1, central enhancement on CT or MRI and immunostaining of S-100 protein and Ki-67 were significantly different between BPNST and MPNST (Table 3) .
DISCUSSION
While optimal treatment of MPNST involves en-bloc surgical resection so as to include surrounding nerves, with or without radiotherapy, BPNST can usually be resected without neurological deficit. BPNSTs around the pelvis often develop large lesions. Moreover, imaging studies reveal an inhomogeneous, hypervascular, bone-destructive tumoral mass; consequently, differentiation from MPNST is often difficult (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
This study demonstrated that MPNST around the pelvis is very rare in patients without neurofibromatosis. Twelve and four cases of BPNST and MPNST, respectively, in the absence of NF were observed in the present study. On the other hand, seven cases each of BPNST and MPNST with NF were observed. The true ratio of BPNST to MPNST in NF patients is unclear due to the rarity of treatment of non-symptomatic tumors in patients with NF. However, the clinician should consider the possibility of MPNST when pelvic tumors in NF patients produce these symptoms.
It has been reported that in the extremities, careful clinical and imaging examinations could distinguish between most benign and malignant peripheral nerve sheath tumors (8) . Pain at rest or neurological deficit is often observed in MPNST; in contrast, BPNST seldom produces these clinical signs in the extremities (11) . However, our data indicate that pain at rest, tumor size and duration of symptoms possess little value in terms of differentiation of BPNST from MPNST around the pelvis. Pelvic PNST tend to be larger in size than PNST in the extremities; in addition, pelvic PNST often arise from the sacral foramen. As a result, both benign and malignant PNST may produce pain. Although faint motor weakness (MMT 4) was occasionally present in patients with BPNST, severe motor weakness (MMT 0-2) was observed exclusively in patients with MPNST. Therefore, evaluation of motor weakness is important with respect to differentiation of benign and malignant tumors.
IMAGING AND HISTOLOGICAL FINDINGS
Most previous reports have stated that imaging studies offer some benefit in terms of differentiation of BPNST from MPNST (8) (9) (10) . It has been documented that 40-50% of BPNSTs occurring in the extremities display central enhancement pattern (8) . Histologically, the pattern comprises a central zone of tightly packed cellular components (Antoni A area in schwannoma) surrounded by hypocellular myxoid material (Antoni B area in schwannoma). This zoning also corresponds to the target sign in T2-weighted MR images, which consists of a central low signal intensity with a peripheral ring of high signal intensity. The central enhancement and target sign are rarely observed in MPNST (12) (13) (14) . In this series, central enhancement was apparent in half of the BPNST cases; however, it was present in only one of the 11 cases of MPNST. In general, large mesenchymal tumors often show degenerative changes at the tumoral center; enhancement is usually evident at the periphery of the tumor. Therefore, central enhancement and target sign have diagnostic value in BPNST (12) . Although the target sign was scarcely observed in CT, central enhancement was often present in CT as well as in MRI.
Degenerative schwannoma, which often arises in this lesion, exhibits cyst formation, hemorrhage, calcification and hyalinization. Imaging findings of degenerative schwannoma also revealed such degenerative changes; moreover, enhancement was observed at the periphery of the tumor. Invasive margin was apparent in three of the 11 MPNSTs; in contrast, no BPNST displayed invasive margin in this series. Although the incidence of invasive margin in MPNST is low, margin of the tumor also possesses diagnostic value.
Preoperative pathological diagnosis based on a limited number of samples is particularly difficult. FNA is often not beneficial with respect to the investigation of degenerative tumors, falsely suggesting malignancy due to cellular atypism and poor sampling from degenerative tissue (15, 16) . Among the 10 cases presenting with FNA in this series, one degenerative schwannoma was overdiagnosed as sarcoma; additionally, five samples failed to provide useful information. These disappointing results may be due to the degenerative nature of pelvic PNST and deep tumoral location. We recently employed core needle biopsy with ASAP needle system in five cases. These five samples exhibited suitable quality and were diagnosed accurately. In instances where the sample showed cytological atypism, additional immunohistochemical analysis was useful for arriving at an accurate diagnosis. However, it is not possible to perform needle biopsy in all patients with pelvic PNST. We performed the needle biopsy under CT guidance, when the needle could be inserted through the posterior approach. Care- ful biopsy planning is needed to prevent complications such as bleeding and intestinal damage.
The S-100 protein is widely used as an immunohistochemical marker for PNST. Although S-100 protein can be identified in 50-90% of MPNSTs, staining is typically focal and limited to a small number of cells. Strong, diffuse immunoreactivity for S-100 protein always suggests BPNSTs, including degenerative or cellular schwannomas (17) . The Ki-67 protein is expressed in the proliferative phase (G1, S and G2) of the cell cycle. Ki-67 indices were reported in 5-65% of MPNSTs; in contrast, indices for BPNST were typically less than 5% (18) . In this series, strong, diffuse immunoreactivity for S-100 protein was observed exclusively in BPNST, and over 5% of Ki-67 index was observed solely in MPNST. Therefore, these immunohistochemical analyses offer a powerful tool with respect to differentiation of BPNST from MPNST. Core biopsy specimens provide suitable quality for immunohistochemical analysis. Although all patients included in the present study, who underwent core needle biopsy, complained of radiating pain along the nerves, no neurological deficits were observed following the biopsy. Clinicians should be aware that the needle tract of a biopsy is often contaminated by tumor cells, and it should be resected or irradiated when the tumor is malignant.
Positron emission tomography employing the glucose analogue 18F-fluorodeoxyglucose (18FDG PET), which is a dynamic imaging technique, has been reported to be a useful tool for the detection of MPNST in patients presenting with NF (19) . Although we have no experience with 18FDG PET, a dynamic study of this caliber may improve diagnostic accuracy.
Differentiation of BPNST from MPNST remains problematic. However, careful evaluation of motor weakness, recognition of central enhancement in BPNST, core needle biopsy and immunohistochemical examination possess diagnostic value in terms of differentiation of benign and malignant PNST.
